hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06380790 id: 8423 briefTitle: Effect of Laser-aided Csf on the Rate of Leveling and Alignment of Mandibular Anterior Crowding overallStatus: RECRUITING date: 2023-05-01 date: 2024-05 date: 2024-10 date: 2024-04-24 date: 2024-04-24 name: Cairo University class: OTHER briefSummary: To test the effect of laser-aided circumferential supracrestal fiberotomy on the rate of leveling and alignment conditions: Orthodontics studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 26 type: ESTIMATED name: Laser-aided csf name: placebo laser-aided csf measure: Rate of tooth movement measure: Pain level measure: Periodontal health sex: FEMALE minimumAge: 18 Years maximumAge: 25 Years stdAges: ADULT facility: Faculty of dentistry cairo university status: RECRUITING city: Cairo country: Egypt name: Cairo University role: CONTACT phone: 0223638755 email: ortho@dentistry.cu.edu.eg lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06380777 id: DDT system for sarcopenia briefTitle: Establishment and Application of Digital Diagnosis and Treatment System for Sarcopenia overallStatus: RECRUITING date: 2023-09-01 date: 2028-12-31 date: 2028-12-31 date: 2024-04-24 date: 2024-04-24 name: Peking Union Medical College Hospital class: OTHER briefSummary: The goal of this observational study is to establish a digital diagnosis and treatment system for sarcopenia, integrating research outcomes into a unified approach encompassing a digital vaccine (early warning screening model), digital drug (intervention model associated with pathogenesis), and digital rehabilitation (preventive system combining early warning and treatment). This aims to create a digital visual tertiary prevention network for sarcopenia.
Key outcomes will focus on sarcopenia indicators, serum biomarkers, and clinical endpoints such as fracture rates, weakness classification, and quality of life. conditions: Sarcopenia studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 10000 type: ESTIMATED measure: Appendicular skeletal muscle mass index measure: Hand grip strength measure: Gait speed measure: Concentration of insulin measure: Concentration of adiponectin measure: Concentration of leptin measure: Concentration of insulin like growth factor -1(IGF-1) measure: Concentration of interleukin 18 (IL-18) measure: Concentration of tumor necrosis factor - α (TNF-α) measure: Concentration of TNF-like weak inducer of apoptosis (TWEAK) measure: Concentration of fibroblast growth factor -19 (FGF-19) measure: Concentration of myostatin measure: Concentration of chemoattractant protein-1 (MCP-1) measure: Concentration of activin sex: ALL minimumAge: 45 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Peking Union Medical College Hospital status: RECRUITING city: Beijing state: Beijing zip: 100730 country: China name: Kang Yu, MD role: CONTACT phone: +86 010-69155550 email: yuk1997@sina.com lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06380764 id: RC.11.3.2024 briefTitle: Greater Occipital Nerve Block Value in Management of Postdural Puncture Headache overallStatus: COMPLETED date: 2023-03-02 date: 2023-07-25 date: 2023-12-01 date: 2024-04-24 date: 2024-04-24 name: Benha University class: OTHER briefSummary: Neuraxial techniques are well tolerated and effective options for labor analgesia and anesthesia for caesarean section, and may protect high risk women against severe maternal morbidity. However, neuraxial techniques still have drawbacks especially postdural puncture headache (PDPH) and may be associated with chronic headache, back pain and postnatal depression. PDPH is a relatively common acute complication of neuraxial techniques that was traditionally considered benign and self-limiting, but it significantly impacts patients' general health and quality of life.
Greater Occipital Nerve (GON) originates from C2-3 segments and through its muscular relations it is divided as proximal and distal parts; the most proximal part lies between obliquus capitis inferior and semispinalis and then passes through the semispinalis to pierce the trapezius muscle. In distal region of trapezius fascia, the GON is crossed by the occipital artery and exits the trapezius fascia into the nuchal line about 5-cm lateral to midline. Functionally, GON provides motor supplies to the muscles while passing through it and its main sensory supply is in the occipital region. conditions: Postdural Puncture Headache studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: SINGLE whoMasked: PARTICIPANT count: 152 type: ACTUAL name: Greater Occipital Nerve Block name: Bilateral suboccipital intramuscular injection name: Epidural Blood Patch name: Normal Saline 10 mL Injection name: Lidocaine 2% Injectable Solution measure: The extent of reduction of consumed analgesia sex: ALL minimumAge: 25 Years maximumAge: 55 Years stdAges: ADULT facility: Benha university city: Banhā state: El Qalyoubia zip: 13511 country: Egypt lat: 30.45906 lon: 31.17858 hasResults: False
nctId: NCT06380751 id: D9722C00001 briefTitle: Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer acronym: EvoPAR-BR01 overallStatus: NOT_YET_RECRUITING date: 2024-04-18 date: 2029-03-30 date: 2030-07-18 date: 2024-04-24 date: 2024-04-24 name: AstraZeneca class: INDUSTRY briefSummary: The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+, 2+/ ISH non-amplified) advanced breast cancer. conditions: Advanced Breast Cancer studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE maskingDescription: Open label count: 500 type: ESTIMATED name: Saruparib (AZD5305) name: Camizestrant name: Abemaciclib name: Ribociclib name: Palbociclib name: Fulvestrant name: Letrozole name: Anastrozole name: Exemestane measure: Progression-Free Survival measure: Overall Survival measure: Progression Free Survival 2 measure: Time to chemotherapy measure: Objective Response Rate measure: Duration of Response measure: Participant-reported tolerability measure: Time to deterioration in patient-reported global health status/QoL as measured by the global health status/QoL scale within the The European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ) measure: Change from baseline in patient-reported global health status/QoL as measured by the global health status/QoL scale within the The European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ) measure: Plasma concentrations of saruparib (AZD5305) measure: Plasma concentrations of camizestrant measure: Samples will be used to develop companion diagnostics by analyzing their performance characteristics and calculate their consistency with clinical trial assays used for enrolment onto the study. sex: ALL minimumAge: 18 Years maximumAge: 130 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Research Site city: Toronto state: Ontario zip: M5G 2M9 country: Canada lat: 43.70011 lon: -79.4163 facility: Research Site city: Montreal state: Quebec zip: H3T 1E2 country: Canada lat: 45.50884 lon: -73.58781 facility: Research Site city: Montréal state: Quebec zip: H2X 0A9 country: Canada lat: 45.50884 lon: -73.58781 facility: Research Site city: Saskatoon state: Saskatchewan zip: S7N 4H4 country: Canada lat: 52.13238 lon: -106.66892 facility: Research Site city: Toronto zip: M4N 3M5 country: Canada lat: 43.70011 lon: -79.4163 hasResults: False
nctId: NCT06380738 id: D0817R00074 id: D0817R00074 type: OTHER domain: AstraZeneca briefTitle: Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed) acronym: PROceed overallStatus: RECRUITING date: 2024-02-14 date: 2027-01-31 date: 2027-01-31 date: 2024-04-24 date: 2024-04-24 name: AstraZeneca class: INDUSTRY name: Merck Sharp & Dohme LLC briefSummary: PROceed is a multisite, prospective, observational study that describes the real-world use and clinical experience of mCRPC patients treated with the combination of olaparib and abiraterone in the mCRPC setting. Clinical outcomes will be assessed in patients who are either NHA-naive or NHA-exposed prior to initiating olaparib + abiraterone treatment, respectively. Patient demographic and clinical characteristics, as well as treatment received prior and subsequent to olaparib + abiraterone, will also be described. The study plans to enroll patients for a maximum of 2 years and follow up patients from initiation of olaparib until 1 year post last patient in. conditions: Metastatic Castration-resistant Prostate Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 250 type: ESTIMATED measure: Time to treatment discontinuation measure: Time to first subsequent therapy sex: MALE stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Research Site status: RECRUITING city: Aschaffenburg country: Germany lat: 49.97704 lon: 9.15214 facility: Research Site status: RECRUITING city: Berlin country: Germany lat: 52.52437 lon: 13.41053 facility: Research Site status: NOT_YET_RECRUITING city: Berlin country: Germany lat: 52.52437 lon: 13.41053 facility: Research Site status: RECRUITING city: Duisburg country: Germany lat: 51.43247 lon: 6.76516 facility: Research Site status: NOT_YET_RECRUITING city: Franckfurt country: Germany facility: Research Site status: RECRUITING city: Halle country: Germany lat: 51.48159 lon: 11.97948 facility: Research Site status: RECRUITING city: Herzogenaurach country: Germany lat: 49.56798 lon: 10.88565 facility: Research Site status: NOT_YET_RECRUITING city: Leipzig country: Germany lat: 51.33962 lon: 12.37129 facility: Research Site status: NOT_YET_RECRUITING city: Lueneburg country: Germany lat: 53.2509 lon: 10.41409 facility: Research Site status: RECRUITING city: Muhlheim country: Germany lat: 50.11667 lon: 8.83333 facility: Research Site status: RECRUITING city: Nurnberg country: Germany lat: 49.45421 lon: 11.07752 facility: Research Site status: RECRUITING city: Russelsheim country: Germany lat: 49.98955 lon: 8.42251 facility: Research Site status: RECRUITING city: Speyer country: Germany lat: 49.32083 lon: 8.43111 facility: Research Site status: RECRUITING city: Wetzlar country: Germany lat: 50.56109 lon: 8.50495 hasResults: False
nctId: NCT06380725 id: jshim8zay6vd briefTitle: The Treatment of High Intensity Transcranial Current Stimulation for Alzheimer's Disease overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-08 date: 2024-12 date: 2024-04-24 date: 2024-04-24 name: Anhui Provincial Hospital class: OTHER_GOV briefSummary: Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive cognitive dysfunction and behavioral impairment. It is currently the most common type of dementia in the old age. At present, the clinical treatment of Alzheimer's disease is expensive and has side effects, so it is very important to explore new methods of treatment for AD. Investigators designed a prospective, randomized, double-blinded and placebo-controlled trial to investigate the effect of transcranial alternating current stimulation (tACS) on cognitive function in AD patients and to assess the biological effectiveness of the treatment. conditions: Alzheimer's Disease conditions: Mild Cognitive Impairment conditions: Dementia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Investigators designed a randomized double-blinded placebo-controlled trial by randomly dividing subjects into two groups: one is the treatment group and the other is the placebo group. primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: Investigators designed a double-blinded trial in which neither the investigator nor the subjects know whether they will be received the treatment or a placebo. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 60 type: ESTIMATED name: Transcranial alternating current stimulation(real stimulation) name: Transcranial alternating current stimulation(sham stimulation) measure: Cognitive appraisal measure: Global Cognitive appraisal measure: Psychobehavioral assessment measure: Near-infrared spectroscopy measure: Event related potential measurement measure: Peripheral blood biomarkers measure: Magnetic Resonance Imaging measure: Incidence of side effects sex: ALL minimumAge: 45 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06380699 id: HJG-CZQH-QHRD106-I briefTitle: Study to Assess PK, Safety and Tolerability in Healthy Subjects overallStatus: COMPLETED date: 2023-03-16 date: 2023-11-16 date: 2023-12-25 date: 2024-04-24 date: 2024-04-26 name: Changzhou Qianhong Bio-pharma Co., Ltd. class: INDUSTRY briefSummary: The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of QHRD106 in Chinese healthy subjects with single and multiple doses. conditions: Acute Ischemic Stroke studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 56 type: ACTUAL name: QHRD106 Injection name: Yurekline name: placebo measure: Safety as assessed by incidence, severity, and causality of adverse events measure: Plasma measurements of QHRD106 measure: Concentration of bradykinin in plasma sex: ALL minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: Nanjing Drum Tower Hospital city: Nanjing state: Jiangsu zip: 210008 country: China lat: 32.06167 lon: 118.77778 hasResults: False
nctId: NCT06380686 id: AIO-KHT-0322/ass briefTitle: Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome acronym: HEAT overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2029-05 date: 2030-05 date: 2024-04-24 date: 2024-04-24 name: AIO-Studien-gGmbH class: OTHER name: Merck Sharp & Dohme LLC briefSummary: Prospective, open, non-interventional, multi-center clinical registry study with the aim to establish a comprehensive research platform reflecting the real-world treatment landscape for recurrent/metastatic head and neck tumor patients. conditions: Squamous Cell Carcinoma of the Oral Cavity conditions: Squamous Cell Carcinoma of the Oropharynx conditions: Squamous Cell Carcinoma of the Hypopharynx conditions: Squamous Cell Carcinoma of the Larynx studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 120 type: ESTIMATED name: data collection measure: Sociodemographic factors measure: Treatments measure: Response rates measure: Treatment decision measure: Progression-free survival measure: Time-to-treatment-failure measure: Overall survival sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Universitätsklinikum Essen city: Essen zip: 45147 country: Germany name: Victor Grünwald, Prof. Dr. role: CONTACT phone: +49 201 723 85584 email: viktor.gruenwald@uk-essen.de lat: 51.45657 lon: 7.01228 hasResults: False
nctId: NCT06380673 id: s68299 briefTitle: Stepwise Heat-Denaturated Protein Introduction for Tolerance Induction in Food Allergy acronym: TEHITI overallStatus: RECRUITING date: 2024-04-22 date: 2028-12-30 date: 2029-12-30 date: 2024-04-24 date: 2024-04-24 name: Universitaire Ziekenhuizen KU Leuven class: OTHER briefSummary: This interventional study aims to validate an early heated protein introduction protocol in cow's milk allergic children who already developed tolerance towards extensively heated cow's milk, in order to speed up the development of complete cow's milk tolerance. Natural complete tolerance induction towards cow's milk takes several years of strict cow's milk avoidance with high risk of anaphylaxis by accidental cow's milk intake. By shortening the time towards complete tolerance, not only the quality of life of both children and parents ameliorates drastically, the time frame for potential anaphylactic reactions is also strongly reduced and can be considered as a preventive strategy to reduce allergic reactions too. Moreover, this strategy has proved efficient for hen's egg allergy. The main question this study wants to answer is whether a 12 months stepwise heated cow's milk introduction (either by gradual reduction of the cooking time or by the use of the Flemish Milk Ladder) in 20'-cooked cow's milk tolerant subjects, results in a larger proportion of complete cow's milk tolerant children after 12 months compared to natural tolerance induction (with 20' cooked milk introduction only). conditions: Food Allergy conditions: Cow Milk Allergy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: DIAGNOSTIC masking: NONE count: 90 type: ESTIMATED name: Implementation of cow's milk in decreasingly heated forms name: Implementation of heated cow's milk name: No intervention measure: Complete cow's milk tolerance after 12 months of stepwise heated cow's milk introduction measure: Time to complete tolerance in all three arms measure: Quality of life in all three arms measure: Clinical reactions measure: Side effects measure: IL-10-producing cow's milk specific regulatory T and B cells measure: BATs to mimic the outcome of cow's milk provocation tests sex: ALL minimumAge: 1 Year maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Imelda Hospital Bonheiden status: RECRUITING city: Bonheiden country: Belgium name: Katrien Coppens, MD role: CONTACT lat: 51.02261 lon: 4.54714 facility: AZ Sint-Jan status: RECRUITING city: Brugge country: Belgium name: Kate Sauer, MD role: CONTACT lat: 51.20892 lon: 3.22424 facility: AZ Maria Middelares status: RECRUITING city: Ghent country: Belgium name: Jasmine Leus, MD role: CONTACT lat: 51.05 lon: 3.71667 facility: Jessa Hospital status: RECRUITING city: Hasselt country: Belgium name: Sophie Verelst, MD role: CONTACT lat: 50.93106 lon: 5.33781 facility: UZ Leuven Gasthuisberg status: RECRUITING city: Leuven country: Belgium name: Dominique MA Bullens, Prof. Dr. role: CONTACT phone: +32016343801 email: dominique.bullens@kuleuven.be lat: 50.87959 lon: 4.70093 hasResults: False
nctId: NCT06380660 id: ACE-106-001 briefTitle: Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors overallStatus: RECRUITING date: 2024-03-22 date: 2028-12-21 date: 2029-03-21 date: 2024-04-24 date: 2024-04-24 name: Acerand Therapeutics (Shanghai) Limited class: INDUSTRY briefSummary: The purpose of this study is to determine if the experimental treatment with poly-ADP ribose polymerase (PARP) inhibitor, ACE-86225106 is safe, tolerable and has anti-cancer activity in adult patients with advanced solid tumors. conditions: Solid Tumor, Adult conditions: BRCA1 Mutation conditions: BRCA2 Mutation conditions: Ovarian Cancer conditions: Breast Cancer conditions: Prostate Cancer studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 298 type: ESTIMATED name: ACE-86225106 tablet measure: Number of participants experiencing adverse events (AEs)/serious adverse events (SAEs) measure: The number of patients experiencing dose limiting toxicity (DLT), as defined in the protocol measure: Recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD) measure: Objective Response Rate (ORR) measure: Duration of Response (DoR) and Time to Response (TTR) measure: Progression Free Survival (PFS) measure: Overall Survival (OS) measure: Pharmacokinetic (PK) parameters and Pharmacodynamic (PD) marker change measure: Serum tumor marker change: CA125, etc. (OC), prostatic specific antigen (PSA, prostate cancer) decreased, and specific tumor markers for other tumor types may also be included (to be assessed by clinical investigators) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fujian Cancer Hospital status: RECRUITING city: Fuzhou state: Fujian country: China lat: 26.06139 lon: 119.30611 facility: Sun Yat-Sen University Cancer Center status: NOT_YET_RECRUITING city: Guangzhou state: Guangdong country: China lat: 23.11667 lon: 113.25 facility: Hubei Cancer Hospital status: RECRUITING city: Wuhan state: Hubei country: China lat: 30.58333 lon: 114.26667 facility: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology status: NOT_YET_RECRUITING city: Wuhan state: Hubei country: China lat: 30.58333 lon: 114.26667 facility: Hunan Cancer Hospital status: RECRUITING city: Changsha state: Hunan country: China lat: 28.19874 lon: 112.97087 facility: Fudan University Shanghai Cancer Center status: RECRUITING city: Shanghai state: Shanghai country: China lat: 31.22222 lon: 121.45806 facility: Zhejiang Cancer Hospital status: RECRUITING city: Hangzhou state: Zhejiang country: China lat: 30.29365 lon: 120.16142 hasResults: False
nctId: NCT06380647 id: 0004 briefTitle: Comparison of Prophylactic Acyclovir and Placebo in Prevention of Eczema Herpeticum in Pediatric Burns acronym: childburn overallStatus: COMPLETED date: 2019-10-01 date: 2020-09-30 date: 2020-09-30 date: 2024-04-24 date: 2024-04-24 name: King Edward Medical University class: OTHER briefSummary: Introduction: Early detection is important in treating patients with Eczema Herpeticum (EH), which may arise in paediatric burn patients. As soon as a clinical diagnosis is confirmed, antiviral medications should be started to ensure an early resolution of the disease. Several studies have indicated that acyclovir is the best treatment for EH lesions in the majority of individuals.
Objective: Compare efficacy of the prophylactic acyclovir and placebo in preventing eczema Herpeticum in paediatric burn patients conditions: Herpes Virus Infection studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Sample size of 64 patients (32 patients in each group) was estimated by using 5% level of significance, 90% power of test with expected percentage of patients given prophylactic acyclovir as 81.3% and patients given placebo as 42.9%. primaryPurpose: PREVENTION masking: SINGLE maskingDescription: parents were blinded to group allocation whoMasked: PARTICIPANT count: 64 type: ACTUAL name: Intravenous Acyclovir measure: Number of participants with positive Tzanck smear sex: ALL minimumAge: 1 Month maximumAge: 13 Years stdAges: CHILD facility: department of pediatric surgery King Edward Medical University city: Lahore state: Punjab zip: 54000 country: Pakistan lat: 31.558 lon: 74.35071 hasResults: False